Manufacturing

mRNA-1273.222 has also received FDA EUA for children and adolescents between six and 17 years of age and for adults over the age of 18 years of age.

The R&D analytical solutions will consist of analytical lab services that use USP’s in-house scientific expertise and state-of-the-art facilities at the USP Advanced Manufacturing Technology Lab in Richmond and the USP headquarters facility in Rockville, Md.

The most safe and effective therapies demand the highest data quality.

In this episode of the Drug Solutions Podcast, Chris Spivey interviews executives at Shabas Solutions LLC, who ran the overseas QMM pilot project.

Advances in contamination control are being to mitigate the presence of pollutants in drug products.

One can improve method precision and productivity by replacing one step in sample preparation with an automated approach.

Advancing digital transformation can significantly reduce R&D costs and shorten drug discovery timelines.

Overall industry growth conceals growing numbers of smaller, faster-paced, adaptable corporate structures.

Unique dosage forms, personalized medicine, and flexible manufacturing are possible with 3DP.

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

The ROSS Vertical Blender enables mixing of friable solids.

Steraline’s VFCM100 guarantees sterility throughout the aseptic filling process via a double-wall isolator.

ACP Systems’ quattroClean snow jet technology uses liquid, climate-neutral CO2 for cleanroom cleaning.

Linkam Scientific Instruments’ NEXUS software enables holistic environmental controls in experiments.

Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.

The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.

Webinar Date/Time: Thursday, December 8, 2022 at 11am EST | 10am CST | 8 am PST

The $286 million investment ability is designed to elevate MillioporeSigma’s ability to conduct biosafety testing and analytical development services.

Webinar Date/Time: Mon, Dec 12, 2022 11:00 AM EST

Element has opened a new 7500-ft3 facility that will be used to evaluate aerosolized product efficacy for reducing airborne organisms and viral particles.

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.

The new facility will allow ReiThera to consolidate its competitive position as a leading CDMO specialized in viral vector production.

Avantor is continuing its investment to support the biopharma market with the opening of its new distribution center in Dublin, Ireland.

Address needs for integrated, automated systems and service.

The new Massachusetts facility will strengthen Cytiva’s cell culture services.